Literatur
Llovet J et al. (2007) Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Proc Am Clin Oncol 25: 1s; Abstract 1
Powell BL et al. (2007) Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL). Proc Am Clin Oncol 25: 1s; Abstract 2
Nordlinger B et al. (2007) First results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX-4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc Am Clin Oncol 25: 2s; Abstract LBA5
Slotman B et al. (2007) A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993). Proc Am Clin Oncol 25: 2s; Abstract 4
Escudier B et al. (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. Proc Am Clin Oncol: Abstract 3
DeMatteo et al. (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III Trial ACOSOG Z9001. Proc Am Clin Oncol: Abstract 10079
Dewar JA, Haviland JS, Agrawal RK et al. (2007) Hypofractionation for early breast cancer: First results of the UK standardisation of breast radiotherapy (START) trials. Proc Am Clin Oncol 25: Part II, 964s; Abstract LBA518
Rastogi P et al. (2007) Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H). Proc Am Clin Oncol 25: Part II, 964s; Abstract LBA513
Van Cutsem E et al. (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (CRC): the CRYSTAL trial. Proc Am Clin Oncol 25: 64s; Abstrac 4000
Vermorken J et al. (2007) Erbitux extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy – Results of a randomized phase III (Extreme) study. Proc Am Clin Oncol 25: 64s; Abstract 6091
Danksagung
Für die Unterstützung bei der Aufarbeitung dieser ASCO-Highlights danke ich Herrn Professor W. Wagner, Osnabrück
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehung/en hin: Reisekostenübernahme durch Novartis Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Junker, A. 43. Jahrestagung der American Society of Clinical Oncology 2007. Onkologe 13, 851–857 (2007). https://doi.org/10.1007/s00761-007-1245-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-007-1245-5